Main Article Content

Hansen Nasif
Lia Sartika
Yelly Oktavia Sari

Abstract

In the treatment of non-Hodgkin's lymphoma, a combination of chemotherapy drugs (Cyclophospamide, Doxorubicin, Vincristine, and Prednisone) is commonly used. Chemotherapy can lead to side effects such as nausea and vomiting, which can be uncomfortable for patients and may interfere with their treatment. This study aimed to analyze the usage pattern of antiemetics, the compatibility of antiemetics with the emetogenic risk of combination chemotherapy, and the relationship between antiemetic dosage suitability and RINVR scores (Rhodes Index Nausea Vomiting and Retching). The RINVR instrument consists of 8 questions, which evaluates the duration, frequency, amount/volume, and stress related to nausea or vomiting. The study involved 30 patients and data were collected through telephone interviews and patient's medical records. Statistical tests using the independent T test showed mild nausea and vomiting (0-8) for both acute and delayed symptoms against the condition of post-chemotherapy. A normality of RINVR scores was tested and it was determined that the scores were not normally distributed (p<0.05). In bivariate analysis, it was found that the average RINVR scores for both acute and delayed symptoms did not show statistically significant differences (p>0.05). This suggests chemotherapy with emetogenic combination still causes nausea and vomiting even though appropriate antiemetics have been given.

Downloads

Download data is not yet available.

Article Details

How to Cite
Nasif, H., Sartika, L., & Sari, Y. O. (2023). Study on anti-emetic drug use in lnh patients at one day care room Dr. M Djamil Padang hospital. Journal of Pharmaceutical and Sciences, 6(5-si), 315–322. https://doi.org/10.36490/journal-jps.com.v6i5-si.397
Section
Original Articles

References

American Cancer Society. Cancer Facts & Figures. (2022) https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2022.pdf diakses 19 April 2023.

Dipiro JT, Talbert RL, Yee GC, Matzke G, Wells BC and Posy LM. (2005). Pharmacotherapy : A Pathophysiologic Approach 6th edition. United State of America: The McGraw-Hill Companies;. Hal 701-712

Greer.John P, et al. (2004). Wintrobe”s Clinical Hematology 11th ed. Lippincott William& Wilkins. Philadelphia : 2363 – 2422

Hariyanto BEP, Mantik MFJ, Wahani A. (2015). Kejadian muntah pada penderita kanker yang menjalani pengobatan kemoterapi di RSUP Prof. Dr. R. D. Kandou Manado. Journal e-Clinic.; 3(3).

Hesketh,P.J. (1999). Defining The emetogenicity of cancer chemoterapy regiment: Relevance to clinical Practice. The Oncologist 4(3):191-196

Husband A dan Worsley A. (2007). Nausea and vomiting- pharmacological management. Hospital Pharmacist.; 4.

Jordan K, Sippel C, Schmoll HJ. (2007). Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. The Oncologist.; 12: 1143-1150

Katzung, B. G. (2013). Farmakologi Dasar dan Klinik Ed.12. Penerbit buku Kedokteran EGC. Jakarta: 949 – 974

Kementerian Kesehatan Republik Indonesia. (2011). Kurikulum Pelatihan Penggunaan Obat Rasional (POR). Modul Penggunaan Obat Rasional, Jakarta

Kementerian Kesehatan Republik Indonesia. (2016). Komite Penanggulangan KankerNasional. Panduan Penatalaksanaan Limfoma Non-Hodgkin. Jakarta

Mukarami, E.,Akamatsu, H., Shimokawa, T., Wada , K., & Yamamoto, N.. (2019). Furosemid versus mannitol in japanese patient with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial

NCCN, N. C. (2022). Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care. NCCN Clinical Practice Guidelines in Oncology.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA et al. (2016) MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Annals of Oncology. 2016; 27(5).

Wardani I. (2006). Studi pemakaian Anti emetik pada pasien limfoma non hodgkin yang medapat kemoterapi CHOP diruang rawat singkat RS kanker Dharmais pada periode Juni 2006 – mei 2006.Jakarta: Universitas Indonesia.

Wella. J., Harmi, P., & Fatmadona, R. (2020). Gambaran Skor INVR (Index of Nausea, Vomiting and Retching) pada CINV (Chemotherapy Induced Nausea and Vomiting) Kanker Payudara di RSUP M Djamil Padang. Jurnal Kesehatan Andalas, 8(4).

Worldwide cancer data | World Cancer Research Fund International. (2023). Diakses 6 September 2023, from https://www.wcrf.org/cancer-trends/worldwide-cancer-data/

Yang CK, Wu CE, Liaw CC. (2016). Combination of palonosetron, aprepritant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-basesd therapy. Biomedical Journal.; 39